Skip to main content

Phase 2 Licensing Deal Benchmarks

Median Upfront
$258M
Range: $144M - $365M
Total Deal Value
$1.6B
Range: $1.1B - $2.2B
Royalty Rate
11.8% - 19.3%
Tiered up to 23.3%
Dev Milestones
$345M
Range: $230M - $461M
Model Your Deal

Market Analysis

Phase 2 represents the most active deal-making stage in biopharma licensing, where proof-of-concept data transforms asset valuations. Median total deal values at Phase 2 reach $1.6B, with upfront payments between $144M and $365M. This stage offers the optimal balance of de-risking and upside potential for both licensors and licensees.

Phase 2 deal structures balance upfront and milestone payments effectively. The 16/84 upfront/milestone split reflects moderate clinical risk. Development milestones average $345M, while regulatory milestones of $552M and commercial milestones of $483M reward successful progression to market.

Royalty rates at Phase 2 range from 11.8% to 19.3%, the mid-range of industry norms. Assets with pivotal-ready Phase 2 data (clear efficacy signal, manageable safety, well-defined patient population) command premium terms approaching Phase 3 valuations, while assets with mixed or preliminary data trade at discounts.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average total deal value for Phase 2 licensing?
Phase 2 licensing deals average $1.6B total deal value, ranging from $1.1B to $2.2B. This reflects the proof-of-concept de-risking that occurs at this stage.
How do Phase 2 deal terms compare to Phase 1 and Phase 3?
Phase 2 deals represent a significant step-up from Phase 1, with 50-100% higher total deal values. Phase 3 deals command approximately 40-80% more than Phase 2, reflecting the additional regulatory de-risking. Phase 2 is considered the optimal licensing window for many licensors.
What data quality factors affect Phase 2 deal valuations?
Key factors include statistical rigor of efficacy data, durability of response, safety profile relative to competitors, biomarker data supporting patient selection, and clarity of the Phase 3 development path. Pivotal-ready Phase 2 data can drive valuations approaching Phase 3 levels.
Why is Phase 2 considered the optimal licensing window?
Phase 2 offers the best risk-reward balance for licensing. Licensors have demonstrated proof of concept, commanding meaningful upfronts, while licensees can still capture significant value appreciation through Phase 3 completion and commercialization. This window maximizes total deal value relative to remaining development risk.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Preclinical Deal Benchmarks

View

Phase 3 Deal Benchmarks

View

ADC Deal Benchmarks

View

Oncology Deal Overview 2026

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included